PsiOxus Pursues CAR-T Mirror Image Strategy Into Clinic
Executive Summary
Bankrolled by upfront and milestone payments associated with deals it has with Bristol-Myers Squibb, Oxford, UK-based gene therapy company PsiOxus Therapeutics is targeting two INDs in 2018 and two in 2019. Company CEO John Beadle outlined his near term plans for the unpartnered programs to Scrip during the 2018 Biotech Showcase.